Trillium Therapeutics

$20.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.28 (+13.11%) Today
+$0.63 (+3.20%) As of 10:25 AM UTC after-hours

Why Robinhood?

You can buy or sell TRIL and other stocks, options, and ETFs commission-free!

About TRIL

Trillium Therapeutics Inc. Common Shares, also called Trillium Therapeutics, is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-10001 (Sting Agonist). The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. The listed name for TRIL is Trillium Therapeutics Inc. Common Shares.

CEO
Jan Skvarka
Employees
29
Headquarters
Mississauga, Ontario
Founded
2004
Market Cap
1.74B
Price-Earnings Ratio
Dividend Yield
Average Volume
2.00M
High Today
$20.14
Low Today
$17.91
Open Price
$18.10
Volume
1.99M
52 Week High
$20.14
52 Week Low
$0.29

Collections

TRIL Earnings

-$1.07
-$0.71
-$0.36
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
per share
Actual
-$0.55 per share

You May Also Like